Outcomes of low-dose immune tolerance induction with single-dose rituximab in severe hemophilia A: a single-center retrospective experience
Shaoyu Yin, Hongli Mu, Wen Yang, Zeping Zhou · 2026
Read Outcomes of low-dose immune tolerance induction with single-dose rituximab in severe hemophilia A: a single-center retrospective experience by Shaoyu Yin, Hongli Mu, Wen Yang, Zeping Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13171382.txt.
Description
Shaoyu Yin, Hongli Mu, Wen Yang, and Zeping Zhou report results for a lower-dose treatment plan in severe hemophilia A, in a study from twenty twenty-six. Some patients develop blockers that stop their clotting factor treatment from working. Training the immune system to accept the factor again can remove the blockers, but the immune-calming drug used with it adds side effects and cost when given in full courses.
Their plan used a single dose of that drug with low-dose factor training. Most patients in the small group lost their blockers, in a median time of under ten months. Bleeding episodes fell sharply during treatment. Side effects were mostly mild, and no blocker had returned after two years. The authors call for larger trials.
Catalog record
| CREATOR | Shaoyu Yin, Hongli Mu, Wen Yang, Zeping Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |